Pathological Role of Unsaturated Aldehyde Acrolein in Diabetic Retinopathy

Miyuki Murata1,2, Kousuke Noda1,2* and Susumu Ishida1,2

1 Laboratory of Ocular Cell Biology & Visual Science, Hokkaido University, Sapporo, Japan, 2 Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

With increasing prevalence of diabetes and a progressively aging society, diabetic retinopathy is emerging as one of the global leading causes of blindness. Recent studies have shown that vascular endothelial growth factor (VEGF) plays a central role in the pathogenesis of diabetic retinopathy and anti-VEGF agents have become the first-line therapy for the vision-threatening disease. However, recent studies have also demonstrated that diabetic retinopathy is a multifactorial disease and that VEGF-independent mechanism(s) also underlie much of the pathological changes in diabetic retinopathy. Acrolein is a highly reactive unsaturated aldehyde and is implicated in protein dysfunction. As acrolein is common in air pollutants, previous studies have focused on it as an exogenous causative factor, for instance, in the development of respiratory diseases. However, it has been discovered that acrolein is also endogenously produced and induces cell toxicity and oxidative stress in the body. In addition, accumulating evidence suggests that acrolein and/or acrolein-conjugated proteins are associated with the molecular mechanisms in diabetic retinopathy. This review summarizes the pathological roles and mechanisms of endogenous acrolein production in the pathogenesis of diabetic retinopathy.

Keywords: inflammation, oxidative stress, vascular adhesion protein-1, acrolein, diabetic retinopathy, spermine oxidase

INTRODUCTION

The prevalence of diabetes is increasing worldwide (1) and the global prevalence has been estimated at 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 (2). Diabetic retinopathy (DR) is a retinal microvascular complication caused by diabetes with complex multifactorial pathogenesis. Epidemiological studies have revealed that the prevalence and severity of DR increases with age and duration of diabetes (3). For instance, 23% of patients with type II diabetes have non-proliferative retinopathy after 11–13 years, 41% after 14–16 years, and 60% after 16 years (3). Hence, with increasing diabetes prevalence and a progressively aging society, DR is emerging as one of the global leading causes of blindness.

Early events in DR, such as thickening of the capillary basement membrane and pericyte loss, both of which contribute to vascular instability in the diabetic retina, are well known. The changes in retinal microvasculature are followed by capillary non-perfusion and ischemia-mediated pathology
such as pathologic neovascularization originating from retinal vessels. The pathologic neovascularization due to retinal ischemia causes the formation of fibrovascular tissues at the vitreoretinal surface, which is a hallmark of proliferative diabetic retinopathy (PDR), and leads to severe complications such as vitreous hemorrhage and tractional retinal detachment. Furthermore, retinal ischemia compromises the blood-retinal barrier (BRB) and results in fluid accumulation in the center of the diabetic retina, i.e., diabetic macular edema (DME). During the past few decades extensive efforts have been undertaken to develop therapeutic strategies to control vascular complications in DR.

Recent advances in basic research have demonstrated that vascular endothelial cell growth factor (VEGF) plays a major role in the pathogenesis of DR (4, 5) and clinical application of anti-VEGF agents have dramatically improved the therapeutic outcomes of the vision-threatening disease. Nowadays, anti-VEGF agents have become the standard first-line treatment for DR, in contrast to the past where photocoagulation and vitreous surgery for advanced DR were the only options.

However, accumulating evidence from clinical research has highlighted a patient population with DME that is refractory to anti-VEGF therapy (6). In fact, DME patients who suffer from poor visual acuity caused by sustained exudative changes in the macula despite frequent injections of anti-VEGF agents are often encountered in the clinical setting. This indicates that DR is a multifactorial disease and VEGF-independent mechanisms also underlie many of the pathological changes.

Some of the reported pathological signs in DR include chronic inflammation and oxidative stress (7). Macroscopic signs of inflammation such as redness (Rubor), heat (Calor), swelling (Tumor) and pain (Dolor), are not pathological features in the diabetic retina and the classical definition of inflammation is inadequate to describe the characteristics of DR. However, at a microscopic level, inflammatory responses including vessel dilatation, hemodynamic alteration, exudation and leukocyte accumulation/migration are present in retinal and choroidal tissues during development of DR (8). In addition, there is growing scientific evidence that oxidative stress plays a crucial role in the development of diabetic complications including DR (9).

Therefore, elucidation of “VEGF-independent” pathophysiology in DR is critical to fulfill an unmet medical need for patients with DR refractory to anti-VEGF therapy. In this review, we provide our perspective on the VEGF-independent mechanisms in the pathogenesis of DR, with focus on the unsaturated aldehyde acrolein.

### WHAT IS ACROLEIN?

Acrolein is a highly reactive unsaturated aldehyde that causes protein dysfunction by reacting preferentially with Cys, Lys and His residues of peptide chains via Michael-type reaction (10, 11) (Figure 1A). In acrolein-conjugated proteins, the Lys adduct is a more stable product than the other adducts. One of the major acrolein-Lys adducts, N\(^{-}\)-(3-formyl-3, 4-dehydropiperidino) lysine adduct (FDP-Lys) (Figure 1B), is known as a reactive intermediate that can covalently bind to thiols, including glutathione (GSH), through the retained electrophilic carbonyl moiety (10). Since the reaction of GSH with acrolein and/or FDP-Lys depletes intracellular reserves of GSH, which is a major antioxidant enzyme, acrolein increases oxidative stress by limiting oxidative stress resistance in the body (12). Notably, previous studies have implicated acrolein in a wide range of vascular diseases such as brain infarction (13) and neurodegenerative diseases such as Parkinson’s disease (14) and Alzheimer’s disease (15). Since DR is a representative retinal disease with characteristics of both vascular disease and neurodegenerative disease, in recent years much attention has been paid to acrolein as a possible participant in the pathogenesis of DR.

### ENDOGENOUS ACROLEIN GENERATION

Since acrolein is common in air pollutants such as cigarette smoke, vehicle exhaust and overheated cooking oil, acrolein was previously focused on as an exogenous causative substance in the research of respiratory diseases such as lung cancer (16). However, recent studies including ours have revealed that acrolein is also generated endogenously through peroxidation of unsaturated fatty acids (17) and polyamine metabolism (18), resulting in cell toxicity and oxidative stress. Among the molecules related to endogenous acrolein generation, the current review focuses on two major enzymes, both of which are implicated in the development of DR.

### Vascular Adhesion Protein-1 (VAP-1)

Vascular adhesion protein-1 (VAP-1) is a homodimeric sialylated glycoprotein expressed in vascular endothelial cells and involved in leukocyte transmigration (19–21). Previous studies have elucidated that VAP-1 is crucial in the pathology of systemic inflammatory diseases, including rheumatoid arthritis (22, 23), inflammatory bowel diseases (24), myocardial
infarction (25), and diabetes (26). In ocular tissues, we reported that VAP-1 is localized to endothelial cells of retinal and choroidal vessels (27), and VAP-1 is involved in the molecular mechanisms of acute ocular inflammation and inflammation-associated ocular angiogenesis (28, 29). In addition, we also showed that VAP-1 blockade significantly reduced the transmigration and capillary entrapment of leukocytes in the retina in a diabetic animal model (30). Taken together, our prior research demonstrates that VAP-1 plays a role in the pathogenesis of DR by mediating leukocyte recruitment as a leukocyte adhesion molecule.

VAP-1 also exists as a soluble form (sVAP-1) in mammals and is known to participate in the initiation and development of systemic disorders (31–33). In addition to its role as an adhesion molecule, both membrane and soluble forms of VAP-1 function as semicarbazide-sensitive amine oxidase (SSAO), which oxidizes aliphatic and aromatic primary monoamines and converts them to the corresponding aldehydes with the release of hydrogen peroxide and ammonia (Figure 2) (34). Of note, our subsequent analyses revealed that high glucose, inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) and angiogenic factor VEGF facilitate proteolytic cleavage of the membrane-bound VAP-1 from retinal capillary endothelial cells mediated by matrix metalloproteinase (MMP)-2 and MMP-9 (35, 36), both of which are important in fibrovascular tissue formation (Figure 3) (37). In addition, our in vitro study revealed that sVAP-1 mediates acrolein production via spermine metabolism, a polyamine in retinal endothelial cells (18). Polyamines are low molecular weight polycations that have two or more primary amine groups, and are known to play an important role in cell proliferation and differentiation (38). In mammals, there are three naturally occurring polyamines: putrescine, spermidine, and spermine (39). In patients with PDR, spermine levels are elevated 15-fold in the vitreous fluid compared to non-DR patients (40), indicating that the vitreous cavity is a substrate-enriched environment for sVAP-1. Indeed, sVAP-1 and FDP-Lys are increased and are correlated in the vitreous fluid of patients with PDR (18). Evidence suggests that acrolein is generated by intravitreal sVAP-1 released from retinal capillary endothelial cells in the presence of participant molecules such as inflammatory cytokines and proteinases in eyes with DR.

Spermine Oxidase

Spermine oxidase (SMOX) is a flavin adenine dinucleotide-containing enzyme that catalyzes the oxidative degradation of spermine to produce spermidine, hydrogen peroxides, and 3-aminopropanal (41) that is non-enzymatically converted to acrolein (Figure 4) (42). SMOX is a highly inducible enzyme and its expression is upregulated by inflammatory cytokines, including TNF-α and IL-6 (43, 44), both of which are increased in eyes with PDR. Recent studies have revealed that FDP-Lys is accumulated in Müller glial cells of streptozotocin (STZ)-induced diabetic rats (45) and in migrated glial cells in the fibrovascular tissues obtained from patients with PDR (46). Therefore, both observation in humans and experimental evidence indicate that acrolein is generated and/or accumulates in retinal glial cells under diabetic conditions. However, retinal glial cells lack VAP-1 expression, and the exact mechanism of acrolein generation in these cells was unclear. Recently, our group discovered that SMOX mediates acrolein generation in cultured retinal glial cells, and that hypoxia induces SMOX production via HIF-1 binding to SMOX promoter (47). In addition, the localization of SMOX was seen predominantly in glial cells of fibrovascular tissues (47). In the advanced stage of DR, obliteration of retinal microvasculature elicits a decrease in tissue oxygen concentration (48, 49) and tissue hypoxia induces extensive cellular responses, including neovascularization that eventually results in proliferative changes at the vitreoretinal surface in eyes with DR. Our in vitro study revealed that hypoxia increases FDP-Lys and hydrogen peroxide levels in cultured retinal glial cells, which were abrogated by the potent SMOX inhibitor MDL72527 (47). Overall, the experimental evidence indicates that SMOX produces acrolein through the enzymatic conversion of spermine to spermidine in retinal glial cells under hypoxic conditions and presumably exacerbates oxidative stress in eyes with DR.

**FIGURE 2** | Enzymatic oxidation of spermine mediated by vascular adhesion protein-1 (VAP-1) function as semicarbazide-sensitive amine oxidase (SSAO). VAP-1 converts spermine to acrolein and hydrogen peroxide, both of which increase oxidative stress in the body.
So far, it has been demonstrated that acrolein plays a significant role in the pathogenesis of systemic disorders, such as neurodegenerative diseases (50), cardiovascular diseases (51), and diabetes (52). With respect to diabetes, acrolein was reportedly increased in the serum and urine of patients with diabetes (52, 53). In the eye, previous studies demonstrated that FDP-Lys markedly increased in retinal glial cells of experimental diabetic rodents (45, 54, 55). We also reported that FDP-Lys was elevated in the vitreous fluid of patients with PDR (18). In addition, we found that FDP-Lys largely accumulated in glial cells (46) and endothelial cells (18) of fibrovascular tissues obtained from patients with PDR. Therefore, these data suggest that acrolein participates in the development of DR.

**FIGURE 3** | Sequential steps of release of the soluble form of VAP-1 from retinal capillary endothelial cells. (A) VAP-1 and other leukocyte adhesion molecules facilitate leukocyte recruitment upon inflammation. (B) Recruited leukocytes secrete inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and vascular endothelial cell growth factor (VEGF). (C) MMP-2 and MMP-9 induced by the inflammatory cytokines proteolytically cleave the VAP-1 protein. (D) Soluble form of VAP-1 was released from the surface of endothelial cells.

**FIGURE 4** | A schematic of oxidative degradation of spermine by spermine oxidase (SMOX). SMOX catalyzes spermine and produces spermidine, hydrogen peroxides, and 3-aminopropanal, which is non-enzymatically converted to acrolein.

**ROLES OF ACROLEIN IN DR**

So far, it has been demonstrated that acrolein plays a significant role in the pathogenesis of systemic disorders, such as neurodegenerative diseases (50), cardiovascular diseases (51), and diabetes (52). With respect to diabetes, acrolein was reportedly increased in the serum and urine of patients with diabetes (52, 53). In the eye, previous studies demonstrated that FDP-Lys markedly increased in retinal glial cells of experimental diabetic rodents (45, 54, 55). We also reported that FDP-Lys was elevated in the vitreous fluid of patients with PDR (18). In addition, we found that FDP-Lys largely accumulated in glial cells (46) and endothelial cells (18) of fibrovascular tissues obtained from patients with PDR. Therefore, these data suggest that acrolein participates in the development of DR.
Inflammation
Recent studies have shown that chronic, low-grade inflammation underlies much of the vascular complications of DR (56, 57). Previously, it was demonstrated that acrolein activated the NF-κB pathway and induced pro-inflammatory cytokines including cyclooxygenase-2 (58). In addition, it was shown that acrolein induced pulmonary inflammation and death of lung epithelial cells via induction of NF-κB signaling in a mouse in vivo study (59). Acrolein also induced TNF-α, IL-6, and IL-8 mRNA expression through NF-κB activation in human umbilical vein endothelial cells (HUVECs) (60).

In the retina, it was reported that acrolein induced transforming growth factor beta-1 (TGFβ1), TGFβ2, and VEGF production in retinal pigment epithelium in hyperglycemic conditions (61). In contrast, an acrolein-scavenging agent significantly suppressed C-C motif chemokine ligand 2 (Ccl2), IL-1β, and intercellular adhesion molecule 1 (Icam1) mRNA expression through NF-κB activation in human umbilical vein endothelial cells (HUVECs) (60).

In the following section, we summarize the role of acrolein in the pathogenesis of DR.

Increase in Oxidative Stress
The role of oxidative stress in the pathogenesis of DR has been extensively investigated in experimental and clinical studies. The levels of various reactive oxygen species (ROS), including superoxide (62) and hydrogen peroxide (63), have been shown to be elevated in the retina of diabetic animals. Conversely, the antioxidant defense systems in eyes of patients with DR have been shown to be functionally damaged (64). We previously demonstrated that acrolein reduces the intracellular reserves of GSH, leading to consequent increase in oxidative stress and cell death in retinal microvascular endothelial cells and glial cells (18, 65). Furthermore, the subsequent analysis further revealed that spermine oxidation by VAP-1 or SMOX results in acrolein generation and exacerbates oxidative stress in the microenvironment by both limiting the anti-oxidant defense system and enhancing ROS generation (18, 47). As aforementioned, VAP-1 and FDP-Lys are increased and are correlated in the vitreous fluid of patients with PDR (18). VAP-1 and N epsilon-(hexanoyl)lysine (HEL), an oxidative stress marker, are also correlated in the vitreous fluid from PDR patients (35). These data indicate that increased acrolein generated by VAP-1 and SMOX participates in the pathogenesis of DR.

Glia Cell Activation
Glial cell activation is the initial response during the early stages of DR (66, 67) and retinal glial cells are known to proliferate and migrate into the vitreoretinal interface, which eventually leads to fibrovascular tissue formation during PDR progression (68, 69). Acrolein stimulated cell migration of Müller glial cells through induction of C-X-C motif chemokine ligand 1 (CXCL1) protein (65), a member of the C-X-C family of chemokines that promotes neutrophil and tumor cell migration through binding to the receptor C-X-C motif chemokine receptor 2 (CXCR2) (69, 70). It has been previously shown that the vitreous level of CXCL1 was increased in eyes affected by PDR (71) and in the vitreous of diabetic mice (72). In addition, we reported that CXCL1 was localized in GFAP-positive cells of fibrovascular tissues (65). Since FDP-Lys largely accumulates in the glial cells of fibrovascular tissues (46), it suggests that CXCL1 stimulates...
Acrolein plays a significant role in DR and may be an important target for the prevention and treatment of DR. 2-Mercaptoethanesulfonate (MESNA) is a potent thiol-based scavenger of acrolein that has already been used clinically to prevent diabetic retinopathy. Therefore, these data indicate that acrolein is potentially one of the molecules triggering retinal glial cell activation in diabetic eyes.

**Neurodegeneration**

The retinal tissue consists of vascular and neural components. Whereas microvascular changes are integral to the formation and devastating effects of DR, DR has been recently recognized as a neuro-vascular disease. There is a growing body of evidence to indicate that neural components are damaged in the early phase of DR, even in the absence of vascular complications such as retinal hemorrhage and microaneurysm formation (73, 74). Basic research findings obtained from postmortem human specimens (75) and diabetic animals showed that diabetes causes cellular disturbance in neural cells, particularly in retinal ganglion cells (RGC) (76).

As mentioned, SMOX produces acrolein through its enzymatic activity. Liu et al. reported elevated levels of FDP-Lys in the ganglion cell layer and inner nuclear layer of the retina in a diabetic animal model (77). It was shown that SMOX inhibitor MDL72527 reduced the upregulation of FDP-Lys, retinal tissue thinning and RGC loss (77), suggesting that acrolein is potentially involved in the neurodegeneration in diabetic eyes.

**THERAPEUTIC APPROACHES TARGETING ACROLEIN**

As described thus far, acrolein plays a significant role in DR and may be an important target for the prevention and treatment of DR. 2-Mercaptoethanesulfonate (MESNA) is a potent thiol-based scavenger of acrolein that has already been used clinically to prevent urothelial toxicity by inactivating metabolites from antineoplastic agents, such as ifosfamide or cyclophosphamide (78). It was also suggested that inhibitors of acrolein and SMOX are potential therapeutic drugs for the treatment of DR.

**REFERENCES**

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetes Med (1997) 14 Suppl 5:S1–85. doi: 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.0.CO;2-I
2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843
3. Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med (2003) 96 (6):266–72. doi: 10.1258/jrsm.96.6.266
4. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeou TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Opthalmol (1994) 118(4):445–50. doi: 10.1016/0002-9394(94)75794-0
5. Lebherz C, Maguire AM, Auricchio A, Tang W, Aleman TS, Wei Z, et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes (2005) 54(4):1141–9. doi: 10.2337/diabetes.54.4.1141
6. Wykoff CC, Elman MJ, Regillo CD, Ding B, Lu N, Stuol I. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. Ophthalmol (2016) 123(8):1716–21. doi: 10.1016/j.ophtha.2016.04.004
7. Rodriguez ML, Perez S, Mena-Molla S, Desco MC, Ortega AL. Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies. Oxid Med Cell Longev (2019) 2019:4940825. doi: 10.1155/2019/4940825
8. Spijkerman AM, Gall MA, Tarnow L, Twisk JW, Lauritzen E, Lund-Andersen H, et al. Endothelial dysfunction and low-grade inflammation and the progression of
retinopathy in Type 2 diabetes. *Diabetes Med* (2007) 24(9):969–76. doi: 10.1111/j.1464-5419.2007.02171.x

21. Noda K, Nakao S, Ishida S, Ishibashi T. Leukocyte adhesion molecules in diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. *Diabetologia* (2018) 61(6):29–38. doi: 10.1007/s00125-017-4435-8

20. Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. *Mol Nutr Food Res* (2011) 55(9):1301–19. doi: 10.1002/mnfr.201100182

19. Feng Z, Hu W, Hu Y, Tang MS. Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. *Proc Natl Acad Sci U.S.A.* (2006) 103(42):15404–9. doi: 10.1073/pnas.0607031103

18. Ambaw A, Zheng I, Tambe MA, Strathern KE, Acosta G, Hubers SA, et al. Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson’s disease. *Mol Cell Neurosci* (2018) 88:70–8. doi: 10.1016/j.mcn.2018.01.006

17. Uchida K, Kanematsu M, Morimito Y, Osawa T, Noguchi N, Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. *J Biol Chem* (1998) 273(26):16058–66. doi: 10.1074/jbc.273.26.16058

16. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. *Mol Nutr Food Res* (2008) 52(1):7–25. doi: 10.1002/mnfr.200700412

15. Luo J, Shi R. Acrolein induces oxidative stress in brain mitochondria. *Neurochem Int* (2005) 46(3):243–52. doi: 10.1016/j.neuint.2004.09.001

14. Sakki R, Park H, Ishi I, Yoshida M, Nishimura K, Toida T, et al. Brain infarction correlates more closely with acrolein than with reactive oxygen species. *Biochem Biophys Res Commun* (2011) 404(4):1044–9. doi: 10.1016/j.bbrc.2010.12.107

13. Feng Z, Hu W, Hu Y, Tang MS. Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. *Proc Natl Acad Sci U.S.A.* (2006) 103(42):15404–9. doi: 10.1073/pnas.0607031103

12. Akin E, Aversa J, Steere AC. Expression of adhesion molecules in synovia of rheumatoid arthritis patients. *Arthritis Res Ther* (2003) 5(3):177–85. doi: 10.1186/ar780

11. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. *Mol Nutr Food Res* (2011) 55(9):1301–19. doi: 10.1002/mnfr.201100182

10. Aldini G, Orioli M, Carini M, Protein modification by acrolein: relevance to pathological conditions and inhibition by aldehyde sequestering agents. *Mol Nutr Food Res* (2011) 55(9):1301–19. doi: 10.1002/mnfr.201100182

9. Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. *Diabetologia* (2018) 61(6):29–38. doi: 10.1007/s00125-017-4435-8

8. Noda K, Miyahara S, Nakazawa T, Almulki L, Nakao S, Hisatomi T, et al. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. *FASEB J* (2008) 22(4):1094–103. doi: 10.1096/fj.07-9377com
62. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. *Free Radic Biol Med* (2003) 35(11):1491–9. doi: 10.1016/j.freeradbiomed.2003.08.018
63. Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BRB/ Wor diabetic rat. *Free Radic Biol Med* (2000) 28(1):91–101. doi: 10.1016/s0981-5897(99)00216-6

64. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. *Exp Diabetes Res* (2007) 2007:43603. doi: 10.1155/2007/43603

65. Murata M, Noda K, Yoshida S, Saito M, Fujiya A, Kanda A, et al. Unsatuated Aldehyde Acrolein Promotes Retinal Gial Cell Migration. *Invest Ophthalmol Vis Sci* (2019) 60(13):4425–35. doi: 10.1167/iovs.19-27346

66. Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Aqueous Humor Biomarkers of Muller Cell Activation in Diabetic Eyes. *Invest Ophthalmol Vis Sci* (2015) 56(6):3913–8. doi: 10.1167/iovs.15-16554

67. Vujosevic S, Midena E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Muller cells alterations. *J Diabetes* (2013) 5(10):1249–9. doi: 10.1001/jamapi2008.0160100126042

68. Nork TM, Wallow IH, Sramek SJ, Anderson G. Muller’s cell involvement in proliferative diabetic retinopathy. *Arch Ophthalmol* (1987) 105(10):1249–9. doi: 10.1001/archoph.1987.01060100126042

69. Yanoff M, Sassani JW. 15 - Diabetes Mellitus. In: M Yanoff, JW Sassani, editors. *Ocular Pathology, Seventh Edition*. London: W.B. Saunders (2015). p. 527–53.e7.

70. De Filippo K, Henderson RB, Laschinger M, Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. *J Immunol* (2008) 180(6):4308–15. doi: 10.4049/jimmunol.180.6.4308

71. Lange CAK, Stavrakas P, Luhmann UFO, de Silva DJ, Ali RR, Gregor ZJ, et al. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. *Am J Ophthalmol* (2011) 152(3):406–12 e3. doi: 10.1016/j.ajo.2011.02.014

72. Tang J, Allen C, Du Y, Sun Y, Pearlman E, Shebani N, et al. MyD88-dependent pathways in leukocytes affect the retina in diabetes. *PloS One* (2013) 8(7):66871. doi: 10.1371/journal.pone.0066871

73. Della Sala S, Bertoni G, Somazzi L, Stubbe F, Wilkins AJ. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. *Br J Ophthalmol* (1985) 69(2):136–42. doi: 10.1136/bjo.69.2.136

74. Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, Senior B. Contrast sensitivity in diabetics with and without background retinopathy. *Arch Ophthalmol* (1985) 103(1):51–4. doi: 10.1001/archoph.1985.01050010055018

75. Bloodworth JM Jr. Diabetic retinopathy. *Diabetes* (1962) 11:1–22.

76. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neuronal apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. *J Clin Invest* (1998) 102(4):783–91. doi: 10.1172/JCI2425

77. Liu F, Saul AB, Pichavaram P, Xu Z, Rudraraju M, Somanath PR, et al. Pharmacological Inhibition of Spermere Oxidase Reduces Neurodegeneration and Improves Retinal Function in Diabetic Mice. *J Clin Med* (2020) 9(2):340. doi: 10.3390/jcm9020340

78. Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aklas MK, et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. *Drug Metab Dispos* (2002) 30(2):183–90. doi: 10.1124/dmd.30.2.183

79. Narayanan SP, Shosha E C. DP. Spermere oxide: A promising therapeutic target for neurodegeneration in diabetic retinopathy. *Pharmacol Res* (2019) 147:104299. doi: 10.1016/j.phrs.2019.104299

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Murata, Noda and Ishida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.